Protect II, A Prospective, Multicenter Randomized Controlled Trial
Launched by ABIOMED INC. · Nov 20, 2007
Trial Information
Current as of July 25, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Informed consent
- • Subject is indicated for a NON emergent percutaneous treatment of at least on de novo or restenotic lesion in a native coronary vessel or bypass graft.
- * Patient presents with:
- • A compromised Ejection Fraction
- • Intervention on the last patent coronary conduit
- • Intervention on an unprotected left main artery or
- • Patient presenting with triple vessel disease.
- Exclusion Criteria:
- • ST elevation M.I.
- • Pre procedure cardiac arrest within 24 hours.
- • Subject in cardiogenic shock
About Abiomed Inc.
Abiomed Inc. is a leading medical technology company specializing in heart pump and circulatory support devices. With a commitment to advancing patient care, Abiomed develops innovative therapies designed to treat coronary artery disease and heart failure, significantly improving patient outcomes. The company is renowned for its cutting-edge Impella heart pumps, which provide temporary mechanical support for patients undergoing high-risk procedures or experiencing severe cardiovascular events. Through rigorous clinical trials and a dedication to research and development, Abiomed aims to transform the landscape of cardiovascular treatment and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Los Angeles, California, United States
Durham, North Carolina, United States
Birmingham, Alabama, United States
Maywood, Illinois, United States
Detroit, Michigan, United States
Phoenix, Arizona, United States
Houston, Texas, United States
Augusta, Georgia, United States
Cincinnati, Ohio, United States
Miami, Florida, United States
Charlotte, North Carolina, United States
Chicago, Illinois, United States
Amsterdam, , Netherlands
Sayre, Pennsylvania, United States
Takoma Park, Maryland, United States
Rochester, New York, United States
St. Louis, Missouri, United States
Atlanta, Georgia, United States
La Jolla, California, United States
Detroit, Michigan, United States
Lincoln, Nebraska, United States
Ocala, Florida, United States
Murray, Utah, United States
Royal Oak, Michigan, United States
Pittsburgh, Pennsylvania, United States
Edmonton, Alberta, Canada
Houston, Texas, United States
York, Pennsylvania, United States
Southfield, Michigan, United States
New York, New York, United States
Edmonton, Alberta, Canada
Gilbert, Arizona, United States
Boston, Massachusetts, United States
New York,, New York, United States
Fremont, California, United States
Boston, Massachusetts, United States
Boston, Massachusetts, United States
Dearborn, Michigan, United States
Detroit, Michigan, United States
Petoskey, Michigan, United States
Morristown, New Jersey, United States
Winston Salem, North Carolina, United States
Columbus, Ohio, United States
Wormleysburg, Pennsylvania, United States
Dallas, Texas, United States
Bellingham, Washington, United States
Seattle, Washington, United States
Ottawa, Ontario, Canada
Toronto, Ontario, Canada
Montreal, Quebec, Canada
Patients applied
Trial Officials
William O'Neill
Principal Investigator
Not affilicated with Abiomed
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials